Post Profile






Anthem Says It Won't Cover Sarepta's Muscular Dystrophy Drug

Anthem, one of the nation's largest health insurers, said it won’t cover the expensive biotech drug Duchene for muscular dystrophy, saying its “investigational and not medically necessary."
read more

share

Related Posts


Sarepta's Eteplirsen Walks Closer to Success

Business & Finance / Personal Finance : Savings Experiment

Eteplirsen keeps up its steady walk toward approval. Sarepta Therapeutics reported the latest clinical study results today for its Duchenne muscular dystrophy, or DMD, drug. Shares in the biotech are up nearly 5% as the trading day ...

Sarepta's keenly watched muscle dystrophy drug wins FDA approval

Health : Reuters: Health

(Reuters) - Sarepta Therapeutics Inc's Duchenne muscular dystrophy drug won approval from the U.S. Food and Drug Administration on Monday, capping months of regulatory uncertainty and pressure from parents and patient advocates to e...

Sarepta Wins FDA Nod For Embattled DMD Drug -- But With A Catch

Business & Finance : Forbes: Business

Just five days after its main nemesis at the FDA departed the agency, Sarepta Therapeutics has won a long-sought-after approval for eteplirsen, its drug to treat Duchenne muscular dystrophy (DMD). But the company's battle isn't over...

Sarepta Outperformed Biotechs In August Due To Muscular Dystrophy Drug

Industries / Medical : The Medicine Show

Sarepta, the developer of a new muscular dystrophy drug with extremely promising results, saw its shares gain more than any other medical stock in my monthly scan of biotech, pharma, and medical device stocks. This scan, using data ...

Anthem says will not cover Sarepta's approved Duchenne drug

Health : Reuters: Health

(Reuters) - Health insurer Anthem Inc said it will not cover Sarepta Therapeutics Inc's drug to treat the rare condition of Duchenne muscular dystrophy (DMD), calling it "investigational and not medically necessary."

Comments


Copyright © 2016 Regator, LLC